Navigation Links
ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
Date:5/17/2010

LEUVEN, Belgium and LUND, Sweden, May 17, 2010 /PRNewswire-FirstCall/ --

- Trial to Study Patients with Colorectal and Ovarian Cancer

ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS: BINV) announce today that their partner Roche (SIX: RO, ROG; OTCQX: RHHBY) will begin an imaging study with the novel anti-cancer antibody TB-403 (RG7334) in patients with metastatic, treatment-refractory, colorectal and ovarian cancers. ThromboGenics and co-development partner BioInvent will receive a milestone payment of EUR10 million from Roche under the terms of the strategic alliance agreement signed in June 2008. ThromboGenics, which discovered TB-403, receives 60% and BioInvent 40% of all revenue from the alliance with Roche for this anti-cancer antibody.

This trial is a multi-centre, open-label (monotherapy), dose-finding study with intravenous TB-403. The primary objective of the study will be to establish the TB-403 concentration-pharmacodynamic (PD) effect relationship using DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) and to identify the minimally PD effective dose. The trial will recruit up to 50 patients across three European sites.

With the start of this study, Roche will assume responsibility for all future development of TB-403, continuing the work started by ThromboGenics and BioInvent. A Joint Steering Committee made up of representatives from Roche, ThromboGenics and BioInvent will continue to oversee research and development activities. In addition, Roche will continue to provide funding to ThromboGenics and BioInvent for re
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
9. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
10. ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
11. ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Calif. , Aug. 29, 2014 Medina ... as CEO and member of the Board of Directors ... of medical device development and commercialization experience, including over ... Mr. Engelson previously served as a Partner of the ... President and CEO of two Foundry start-ups. Mr. Engelson ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4
... Sept. 21, 2011 Reportlinker.com announces that a ... catalogue: Generic Drugs: The ... http://www.reportlinker.com/p0619264/Generic-Drugs-The-Global-Market-Focus-on-the-Americas.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Machine_Tool_and_Equipment ... examination of the strategies employed by companies specializing ...
... SAN DIEGO, Sept. 20, 2011 Orexigen® Therapeutics, Inc. ... a recent meeting with senior officials in FDA,s Office ... detailing OND,s design requirements for a cardiovascular outcomes trial ... Letter (CRL) received in January 2011. Orexigen believes that ...
Cached Medicine Technology:Generic Drugs: The Global Market: Focus on the Americas 2Generic Drugs: The Global Market: Focus on the Americas 3Generic Drugs: The Global Market: Focus on the Americas 4Generic Drugs: The Global Market: Focus on the Americas 5Generic Drugs: The Global Market: Focus on the Americas 6Generic Drugs: The Global Market: Focus on the Americas 7Generic Drugs: The Global Market: Focus on the Americas 8Generic Drugs: The Global Market: Focus on the Americas 9Generic Drugs: The Global Market: Focus on the Americas 10Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5
(Date:8/29/2014)... (PRWEB) August 29, 2014 As reported by ... Monitoring For Drug Abuse Trends , Outbreaks (8/20), the National ... attempt to monitor drug abuse trends by turning to social ... drug abuse trends, it is also working with the University ... National Drug Early Warning System, which will be funded by ...
(Date:8/29/2014)... Market Research Report on Global ... professional and in-depth market survey on Global and ... the basic information of Glass microfiber including its ... explores global and China’s top manufacturers of Glass ... and market share etc. , The report further ...
(Date:8/29/2014)... August 29, 2014 Dr. Parsa Mohebi M.D. ... of hair loss achieve great results in hair transplantation. ... Hair Transplant , an FUE method that harvests facial hair ... This method lets patients whose hair loss classification is 5 ... Transplant is a great alternative for those advanced hair loss ...
(Date:8/29/2014)... -- Astronauts may be at heightened risk of ... systems, a new study suggests. That could be ... the moon and Mars undertaken in the future, because ... be dangerous, NASA researchers say. They found that ... International Space Station crew members remains relatively unchanged during ...
(Date:8/29/2014)... 2014 Healthpointe Medical Group, one ... medical center from LAXMed. The medical center is less than ... miles west of the 405 freeway. , The LAX ... new LAX center is located at: 8610 S. Sepulveda Blvd., ... Healthpointe LAX office will provide the same comprehensive ...
Breaking Medicine News(10 mins):Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 2Health News:Social Media Proves to Be Helpful in Fighting Drug Abuse 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Global and Chinese Glass Microfiber Industry Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2
... Mayo Clinic review of patients responses to a drug ... general surgery questions a U.S. Food and Drug Administration ... appears in the current issue of the journal Anesthesiology. ... 2001 over concerns that the drug contributed to potentially ...
... This Decade ... OAKLAND, Calif., Sept. 28 Registered nurses at up to 16,Northern ... a major strike in October that could involve up to 5,500 ... Group in Yuba City and Marysville. Strike notices are being ...
... Center at Jefferson in Philadelphia have discovered new molecular ... breast cancer. They have found that prolactin, a pituitary ... initiates a new signaling pathway that may regulate the ... The work, which appears this month in the journal ...
... of William V. Corr, Executive Director, Campaign for,Tobacco-Free ... is a,statement of William V. Corr, Executive Director, ... will fall further behind in protecting,workers and the ... as two,more states - neighboring Maryland and Minnesota ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) announced ... Insurance Group ("EAIG") in the new position of,Regional ... an,indirect wholly-owned subsidiary of EIHI. EAIG entered ... licenses to underwrite in North Carolina, Virginia,Georgia and ...
... Cross,announces it has signed new three-year contracts with ... part of Catholic Health East health care,system, effective ... includes Mercy Fitzgerald Hospital, Mercy,Hospital of Philadelphia, Mercy ... Hospital, as well as Mercy Home Health and ...
Cached Medicine News:Health News:Mayo Clinic study finds FDA warning against antinausea drug droperidol unnecessary 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Jefferson researchers uncover new evidence of prolactin's possible role in breast cancer 2Health News:Maryland, Minnesota Go Smoke-free Oct. 1 - Pennsylvania Overdue in Following Suit 2Health News:Eastern Alliance Insurance Group Appoints Cox Regional Marketing Director for Southeast 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 2Health News:Independence Blue Cross Finalizes New Multi-Year Agreements with Mercy Health System and St. Mary Medical Center 3
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: